Inadequate antimicrobial treatment: An important determinant of outcome for hospitalized patients

被引:455
作者
Kollef, MH
机构
[1] Washington Univ, Sch Med, Div Pulm & Crit Care, Dept Internal Med, St Louis, MO 63110 USA
[2] Barnes Jewish Hosp, Med Crit Care Serv, St Louis, MO 63110 USA
[3] Barnes Jewish Hosp, Resp Care Serv, St Louis, MO 63110 USA
关键词
D O I
10.1086/314079
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Inadequate antimicrobial treatment, generally defined as microbiological documentation of an infection that is not being effectively treated, is an important factor in the emergence of infections due to antibiotic-resistant bacteria. Factors that contribute to inadequate antimicrobial treatment of hospitalized patients include prior antibiotic exposure, use of broad-spectrum antibiotics, prolonged length of stay, prolonged mechanical ventilation, and presence of invasive devices. Strategies to minimize inadequate treatment include consulting an infectious disease specialist, using antibiotic practice guidelines, and identifying quicker methods of microbiological identification. In addition, clinicians should determine the prevailing pathogens that account for the community-acquired and nosocomial infections identified in their hospitals, Clinicians can improve antimicrobial treatment by using empirical combination antibiotic therapy based on individual patient characteristics and the predominant bacterial flora and their antibiotic susceptibility profiles. This broad-spectrum therapy can then be narrowed when initial culture results are received. Further study evaluating the use of antibiotic practice guidelines and strategies to reduce inadequate treatment is necessary to determine their impact on patient outcomes.
引用
收藏
页码:S131 / S138
页数:8
相关论文
共 97 条
  • [91] EFFECT OF SULBACTAM ON INFECTIONS CAUSED BY IMIPENEM-RESISTANT ACINETOBACTER-CALCOACETICUS BIOTYPE ANITRATUS
    URBAN, C
    GO, E
    MARIANO, N
    BERGER, BJ
    AVRAHAM, I
    RUBIN, D
    RAHAL, JJ
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1993, 167 (02) : 448 - 451
  • [92] Comparative in-vitro activity of SCH 27899, a novel everninomicin, and vancomycin
    Urban, C
    Mariano, N
    MosinkaSnipas, K
    Wadee, C
    Chahrour, T
    Rahal, JJ
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1996, 37 (02) : 361 - 364
  • [93] Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment
    Vidal, F
    Mensa, J
    Almela, M
    Martinez, JA
    Marco, F
    Casals, C
    Gatell, JM
    Soriano, E
    deAnta, MTJ
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1996, 156 (18) : 2121 - 2126
  • [94] THE PREVALENCE OF NOSOCOMIAL INFECTION IN INTENSIVE-CARE UNITS IN EUROPE - RESULTS OF THE EUROPEAN PREVALENCE OF INFECTION IN INTENSIVE-CARE (EPIC) STUDY
    VINCENT, JL
    BIHARI, DJ
    SUTER, PM
    BRUINING, HA
    WHITE, J
    NICOLASCHANOIN, MH
    WOLFF, M
    SPENCER, RC
    HEMMER, M
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (08): : 639 - 644
  • [95] New resistance in Staphylococcus aureus
    Waldvogel, FA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (07) : 556 - 557
  • [96] Weinstein MP, 1997, CLIN INFECT DIS, V24, P584, DOI 10.1093/clind/24.4.584
  • [97] Intermittent bolus dosing of ceftazidime in critically ill patients
    Young, RJ
    Lipman, J
    Gin, T
    Gomersall, CD
    Joynt, GM
    Oh, TE
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (02) : 269 - 273